AELIS — Aelis Farma SA Share News
0.000.00%
Last trade - 00:00Brief: Euronext: Quarterly Review Of CAC Family
Brief: Aelis Farma Confirms Its 2025 Outlook
Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117
Brief: Aelis Farma Says AEF0217 Well Tolerated With No Safety Concerns Identified
Brief: Aelis Farma Announces The Results Of Its Clinical Phase 2B Study With Aef0117
Brief: Aelis Farma FY Operating Loss Narrows To EUR 6.5 Mln
Brief: Aelis Farma: Completion Of Patient Randomization For Study With AEF0117 For Treatment Of Cannabis Addiction
Brief: Aelis Farma H1 Net Loss Narrows To EUR 1.6 Million
Brief: Aelis Farma Receives Positive Recommendation To Continue AEF0117 Phase 2B Clinical Study
Brief: Aelis Farma Presented Preclinical Data Showing Efficacy Of AEF0217 In Genetic Mouse Model Of Autism Spectrum Disorder
Brief: Aelis Farma FY Operating Result Turns To Loss Of EUR 8.5 Million
Brief: Aelis Farma Recruits First Patient For Aef0217 Trial In Down Syndrome
Brief: Aelis Farma Announces Positive Results From Its Trials Of AEF0217 In Volunteers
Brief: Aelis Farma H1 Net Result Turns To Loss Of 10.4 Million Euros
Brief: Aelis Farma Enrolls First Patient In Phase 2B Study Of AEF0117
Brief: Aelis Farma FY Operating Loss Turns To Profit Of Eur 2.6 Mln
Brief: Aelis Farma Announces End Of Stabilisation Period
Aelis Farma opens Euronext Paris dance below IPO price